

PRODUCT INFORMATION



Muraglitazar

Item No. 10007853

CAS Registry No.: 331741-94-7

Formal Name: N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-glycine

Synonym: BMS-298585

MF: C₂₉H₂₈N₂O₇


FW: 516.5

Purity: ≥90%

Supplied as: A crystalline powder

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Muraglitazar is supplied as a crystalline solid. A stock solution may be made by dissolving the muraglitazar in the solvent of choice, which should be purged with an inert gas. Muraglitazar is soluble in DMSO and is slightly soluble in chloroform and methanol.

Description

Muraglitazar is a dual agonist of peroxisome proliferator-activated receptor α (PPAR α) and PPAR γ (EC₅₀s = 0.32 and 0.11 μ M, respectively).¹ It is selective for PPAR α/γ over other nuclear receptors, including PPAR δ , RXR α , RARs, estrogen receptor α (ER α), ER β , androgen receptor (AR), and progesterone receptor (PR). Muraglitazar (50 μ M) reduces the size of lipid droplets in oleic acid-treated HepaRG human hepatocytes.² It reduces plasma levels of glucose, triglycerides, free fatty acids, and insulin by 54, 33, 62, and 48%, respectively, in *db/db* mice when administered at a dose of 10 mg/kg per day.¹ Muraglitazar (10 mg/kg per day) reduces plasma levels of glucose, triglycerides, and cholesterol in diet-induced obese mice.³ Muraglitazar also inhibits LPS-induced increases in nitric oxide (NO) production and IL-6, TNF- α , and inducible nitric oxide synthase (iNOS) protein levels in J774 murine macrophages in a concentration-dependent manner.⁴ It inhibits carrageenan-induced paw edema in mice when administered at doses ranging from 12.5 to 50 mg/kg.

References

- Devasthale, P.V., Chen, S., Jeon, Y., *et al.* Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. *J. Med. Chem.* **48(6)**, 2248-2250 (2005).
- Rogue, A., Anthérieu, S., Vluggens, A., *et al.* PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. *Toxicol. Appl. Pharmacol.* **276(1)**, 73-81 (2014).
- Harrity, T., Farrelly, D., Tieman, A., *et al.* Muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β -cell function in *db/db* mice. *Diabetes* **55(1)**, 240-248 (2006).
- Paukkeri, E.-L., Leppänen, T., Lindholm, M., *et al.* Anti-inflammatory properties of a dual PPAR γ /alpha agonist muraglitazar in *in vitro* and *in vivo* models. *Arthritis Res. Ther.* **15(2):R51** (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/12/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM